Ready to start planning your care? Call us at 800-525-2225 to make an appointment.
×

Memorial Sloan Kettering Cancer Center

Make an Appointment
Back
Find a Clinical Trial
Cancer & Treatment
Refer a Patient

ABOUT US

Our mission, vision & core values

Leadership

History

Equality, diversity & inclusion

Annual report

Give to MSK

effects of this gene. In addition, this drug interferes with other pathways that also cause cancer cells to grow, form new blood vessels, and spread to other parts of the body.

In this study, researchers are evaluating the safety and effectiveness of cabozantinib in patients with advanced non-small cell lung cancers that contain the *KIF5B/RET* gene. Cabozantinib is a pill that is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

- Patients must have a confirmed diagnosis of metastatic or inoperable non-small cell lung cancer that contains the KIF5B/RET gene.
- At least 3 weeks must have passed since completion of prior chemotherapy, 2 weeks since other targeted drugs, and 3 months since radiation therapy to the chest and entry into the study.

Patients must be age 18 or older.

For more information and to inquire about eligibility for this study, please contact Dr. Alexander Drilon at 646-888-4206.

Protocol

12-097

Phase

Phase II (phase 2)

Investigator

Alexander Drilon

Co-Investigators

Mark G. Kris

Diseases

Lung Cancer › Lung Cancer, Non-Small Cell

Lung Cancer, Non-Small Cell › Lung Adenocarcinoma

Thoracic › Lung Cancer

Locations

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Commack Nonna's Garden Foundation Center

Memorial Sloan Kettering Basking Ridge

Memorial Sloan Kettering Westchester

Memorial Sloan Kettering Monmouth

ClinicalTrials.gov ID

NCT01639508

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description

Communication preferences
Cookie preferences
Legal disclaimer
Accessibility statement
Privacy policy
Price transparency
Public notices

© 2024 Memorial Sloan Kettering Cancer Center